Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Y Yu

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Zhonghua Yi Xue Za Zhi|August 2, 2017
[Efficacy and tolerance of Memantine monotherapy and combination therapy with Reinhartdt And Sea Cucumber Capsule on agitation in moderate to severe Alzheimer disease]E Y Yu, Z L Liao, Y F Tan, et al.
Chemical Research in Toxicology|November 23, 2000
Structural basis of the antagonism between inorganic mercury and selenium in mammalsJ Gailer, G N George, I J Pickering, et al.
Zhonghua Yi Xue Za Zhi|February 21, 2019
[Different care models and symptom progression of Alzheimer's disease in China]Z L Liao, Y Chen, Y F Tan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 30, 2016
A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancersK N Chi, E Y Yu, C Jacobs, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 29, 2001
Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transferC J Kuo, F Farnebo, E Y Yu, et al.
Prostate Cancer and Prostatic Diseases|January 21, 2015
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxelH H Cheng, R Gulati, A Azad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 2019
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)A Bamias, K Tzannis, L C Harshman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2017
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)A Bamias, K Tzannis, L C Harshman, et al.
ESMO Open|December 6, 2024
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trialJ E Rosenberg, M D Galsky, T Powles, et al.
ESMO Open|August 12, 2025
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinomaM S van der Heijden, T Powles, S Gupta, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Zhonghua Yi Xue Za Zhi|August 2, 2017
[Efficacy and tolerance of Memantine monotherapy and combination therapy with Reinhartdt And Sea Cucumber Capsule on agitation in moderate to severe Alzheimer disease]E Y Yu, Z L Liao, Y F Tan, et al.
Chemical Research in Toxicology|November 23, 2000
Structural basis of the antagonism between inorganic mercury and selenium in mammalsJ Gailer, G N George, I J Pickering, et al.
Zhonghua Yi Xue Za Zhi|February 21, 2019
[Different care models and symptom progression of Alzheimer's disease in China]Z L Liao, Y Chen, Y F Tan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 30, 2016
A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancersK N Chi, E Y Yu, C Jacobs, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 29, 2001
Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transferC J Kuo, F Farnebo, E Y Yu, et al.
Prostate Cancer and Prostatic Diseases|January 21, 2015
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxelH H Cheng, R Gulati, A Azad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 2019
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)A Bamias, K Tzannis, L C Harshman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2017
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)A Bamias, K Tzannis, L C Harshman, et al.
ESMO Open|December 6, 2024
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trialJ E Rosenberg, M D Galsky, T Powles, et al.
ESMO Open|August 12, 2025
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinomaM S van der Heijden, T Powles, S Gupta, et al.
Pageof 3